Navigation Links
Boston Millennia Partners Portfolio Company CardioMEMS Signs Equity Investment and Exclusive Option to be Acquired for an Additional $375,000,000
Date:9/8/2010

BOSTON, Sept. 8 /PRNewswire/ -- Boston Millennia Partners is pleased to announce that its portfolio company, CardioMEMS, Inc., an Atlanta based medical device company, has accepted a $60 million investment from and granted a $375 million purchase option to St. Jude Medical, Inc.

(Logo: http://photos.prnewswire.com/prnh/20100908/NE61309LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100908/NE61309LOGO  )

Boston Millennia Partners is a lead investor in CardioMEMS and has worked with the Company since its first institutional round of financing to build and commercialize a world leading, implantable, wireless sensor platform. The Company recently completed a pivotal PMA directed trial in Congestive Heart Failure (CHF), producing results that are expected to be highly meaningful both for improving clinical outcomes and for reducing cost.

"The CardioMEMS CHAMPION ('CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Patients') Heart Failure System has demonstrated superb clinical, quality of life and cost reduction potential for CHF patients. St. Jude Medical is an excellent partner with whom this technology can be brought to market promptly, improving clinical prospects for patients and cost of care for payers," says Patrick Fortune, Ph.D., a partner at Boston Millennia Partners and member of the CardioMEMS Board of Directors.

The CardioMEMS CHAMPION Heart Failure System is a wireless heart failure sensor that is implanted into the patient's pulmonary artery using a simple, catheter-based technique. This allows a cardiologist to assess cardiac performance via measurement of pulmonary artery pressure (PAP). The implant procedure is fast, simple and can be performed by any physician who does right-heart catheterizations. With CardioMEMS' technology, doctors can obtain this critical information without the need for a cardiac catheterization.  Following the procedure, patients perform wireless measurements of their pulmonary artery pressure from home. The pressure data is immediately transmitted to a secure database and is available for review by the patient's physician or nurse on the CardioMEMS Champion website.

About CardioMEMS, Inc.

CardioMEMS is a medical device company that has developed and is commercializing proprietary wireless sensing and communication technology for the human body. Its technology platform is designed to improve the management of severe chronic cardiovascular diseases such as aneurysms, heart failure and hypertension. CardioMEMS miniature wireless sensors can be implanted using minimally-invasive techniques and transmit cardiac output, blood pressure and heart rate data which are critical to the management of patients. The sensors can be permanently implanted into the heart and blood vessels due to their small size, durability and lack of wires and batteries. Using radiofrequency (RF) energy, the sensors transmit real-time data to external electronic readers, which then communicate this information to the patient's physician. More information about CardioMEMS is located at www.cardiomems.com.

About Boston Millennia Partners

Boston Millennia Partners is a private equity firm which has managed investment partnerships with more than $700 million in capital. From its offices in Boston, Millennia invests in high-growth business in healthcare, life sciences, and business services industries. Typical investments range from $5 to $20 million. The managers at Millennia have funded over 120 companies in the U.S. private equity market since 1980. For more information, please visit http://www.bmpvc.com/.


'/>"/>
SOURCE Boston Millennia Partners
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Childrens Hospital Boston and Particle Sciences Cooperate on Translational Medicine Efforts
2. Boston Scientifics Womens Health Products Featured in Studies at the Joint Annual Meeting of the International Continence Society and International Urogynecological Association
3. Boston Scientific Launches Neuroform EZ(TM) Stent System in U.S. and Europe
4. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
5. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
6. Boston Scientific Announces Japanese Approval for PROMUS(R) Everolimus-Eluting Coronary Stent System
7. Boston Scientific Announces Settlement of DOJ Investigation Relating to Post-Market Surveys Conducted By Guidant
8. Boston Scientific Announces Election of Nelda Connors to Its Board of Directors
9. Boston Scientific Announces Pricing of $2 Billion of Senior Notes
10. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
11. Boston Scientific to Participate in Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... ROCKVILLE, Md. , July 11, 2017  The ... had estimated revenues of approximately $394.1 million in 2016.  ... a trend of solid growth, in particular as a ... oncology clinical practice, and the recent introduction of a ... the need for less-invasive testing of tumor biomarkers to ...
(Date:7/10/2017)... 10, 2017 The Institute for In Vitro ... the recipient of a VITROCELL® inhalation exposure system thanks ... Consortium. The device, which is designed to replace animals ... lung cells to airborne test materials in an environment ... VITROCELL® system for testing combustible tobacco products, as well ...
(Date:7/5/2017)... -- Wolfmet 3D  printed tungsten collimator manufactured by M&I Materials proves ... to progress molecular radiotherapy imaging. In molecular radiotherapy ... accurately quantify the radiation absorbed by those patients undergoing treatment. ... this radiotherapy treatment has been available — that is, until ... ...
Breaking Medicine Technology:
(Date:7/20/2017)... , ... July 20, 2017 , ... Team Type 1 ... to medicine for everyone affected by diabetes, is teaming up with a Microsoft Corp. ... event kicks off on July 24th. , “Team Type 1’s mission overlaps seamlessly ...
(Date:7/20/2017)... ... , ... The Dermatology Clinic announced today the addition of Dr. Scott W. ... LSU, graduating summa cum laude. He attended Emory University School of Medicine in Atlanta ... Dr. Dunbar moved to New York to complete an AGCME-accredited Mohs surgery fellowship to ...
(Date:7/20/2017)... ... July 20, 2017 , ... A budget proposal to switch to an alternate ... - adjustment (COLA) is a bad deal for older and disabled Americans, says ... would grow even more slowly than the conventional one that is currently used to ...
(Date:7/20/2017)... ... July 19, 2017 , ... Med Tech Solutions (MTS), a leading health ... business unit of Constellation Inc., a move that will help the company better serve ... St. Louis, the acquisition is expected to help MTS expand its presence ...
(Date:7/20/2017)... ... 2017 , ... “Fidget”: a fun-filled, action-packed memoir of adventures. “Fidget” is the ... drama teacher who was a summa cum laude graduate of Gardner Webb University. She ... award. After her retirement from public school, Lynn continued to pursue her love for ...
Breaking Medicine News(10 mins):